Related Experiment Video

Updated: Aug 17, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004

Jérôme Fayette1, Jean-Yves Blay

  • 1Hôpital Edouard Herriot, Service d'oncologie médicale, Lyon, France. jfayette@free.fr

Current Opinion in Oncology
|June 4, 2005
PubMed
Abstract

Insights

Molecular alterations in sarcoma cells influence chemotherapy response. Understanding these changes, including gene mutations and translocations, can guide personalized treatment strategies for better outcomes in sarcoma patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Sarcomas are complex cancers managed with surgery, radiation, and chemotherapy.
  • Drug resistance in metastatic sarcoma is a significant clinical challenge.
  • Recent research has uncovered molecular mechanisms underlying this resistance.

Purpose of the Study:

  • To review recent findings on molecular mechanisms of drug resistance in sarcomas.
  • To explore how molecular alterations predict treatment response.
  • To highlight the potential for developing targeted therapies.

Main Methods:

  • Review of recent scientific literature on sarcoma drug resistance.
  • Analysis of molecular pathways involved in apoptosis and drug efflux.
  • Correlation of specific genetic alterations with treatment outcomes.

Main Results:

  • Overexpression of BCL2 family genes and p53 mutations are linked to drug resistance.
  • Multidrug resistance genes facilitate chemotherapeutic agent efflux.
  • Specific sarcoma subtypes exhibit unique resistance mechanisms, such as altered reduced folate carrier expression in osteosarcoma.
  • Gene translocations and mutations (e.g., KIT, PDGFRA) correlate with treatment response, particularly to targeted agents like imatinib.

Conclusions:

  • Tumor cell molecular alterations are key determinants of chemotherapy sensitivity and resistance.
  • Identifying these alterations enables tailored therapeutic strategies for both conventional and targeted treatments in sarcomas.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...